Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good things happening here and good things in the works. $6 here we come. IMO
* * $AGEN Video Chart 11-18-19 * *
Link to Video - click here to watch the technical chart video
* * $AGEN Video Chart 11-11-19 * *
Link to Video - click here to watch the technical chart video
News: $AGEN Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
LEXINGTON, Mass. , Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with Uro...
Read the whole news AGEN - Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
Any members who bought this as Antigenics years ago?
The reason I ask is I did but broker refuses to upgrade it to AGEN.
Any info you could supply would help me straighten it out.
* * $AGEN Video Chart 08-08-2019 * *
Link to Video - click here to watch the technical chart video
Here are some highlights of CC. https://www.webcaster4.com/Webcast/ListenPage?companyId=1556&webcastId=31262
1. One or more ex-US partnerships this year. Agenus to keep US rights.
2. Data this year for PD-1 and CTLA4. Will be presented major Conferences.
3. BLA's for these drugs earlier in 2020 than expected.
4. Next gen CTLA4(1181) increasing response rates from 15% to over 60%.
5. 1181 read-out before end of year.
6. 1181 combination with PD-1 trials before end of year.
7. 1223 into clinic.
8. At least two additional IND's before year-end.
9. Shingrix sales over $1.3 billion. Gates funded manufactured source moving ahead.
10. Agentus IND before yearend. Allogenic pan-cancer vaccine.
Etc.,etc...
News: $AGEN Agenus Milestone Triggers $7.5M Payment
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that ...
Read the whole news Agenus Milestone Triggers $7.5M Payment
News: $AGEN Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
LEXINGTON, Mass. , Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 , and cancer vaccines provided corporate updates and reported financial results for the second quarter of...
Got this from Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
I am new to this stock and to this board. Unless if there are a tremendous number of short on this stock I can't see why the share price is so low. There is a tremendous upside between products in clincal stages and that back in the pipeline. the future seems to be very bright here. I hope so as I will be dropping a lot of coins here.
“Profoundly effective”
We shall see soon...
Everyone who heard what CEO Garo said at the AGM would agree that Agenus's industry leading Next Gen CTLA4 drug (AGEN 1181) is a game changer. Garo said that the company expects this drug to be "profoundly effective". It is expected to be effective in a larger number of patients, in a larger number of indications, in a larger number of combinations, and possibly with a larger margin of safety.
That is why it is significant when Garo said that all of this could be known in as few as "20 to 30 patients". The first patient was dosed 12 weeks ago and there are now 4 sites enrolling patients. If each hospital enrolled one patient a week the enrollment right NOW could be in that 20-30 patient range!
Garo and Jenn were very jacked up during the AGM presentation. My guess is that they already know that this drug is "profoundly effective". More than that I expect that Big Pharma who want to partner also already know this because of their confidentiality agreements.
That is why it is very significant that Garo said that interest in partnering is "at an all time high" and matters are proceeding at "a very, very high pace". My guess is that AGEN 1181 will be the center-piece of multi-Billion dollar partnerships in the near future.
AGENUS AGM TOMORROW
Conference Call and Webcast Information:
Date: Wednesday, June 19, 2019
Time: 5:00 p.m. ET
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus
Live Webcast: accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/30853
A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.
https://ih.advfn.com/stock-market/NASDAQ/antigenics-AGEN/stock-news/79891931/quarterly-report-10-q
"Overview
We are a clinical-stage immuno-oncology (“I-O”) company with a pipeline of immune modulating antibodies, vaccines, adjuvants and adoptive cell therapies - dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. Our business is designed to drive success in I-O through speed, innovation and effective combination therapies. We believe that combination therapies and a deep understanding of each patient’s cancer will drive substantial expansion of the patient population benefiting from current I-O therapies. In addition to a diverse pipeline, we have assembled fully integrated end-to-end capabilities including novel target discovery, antibody generation, cell line development and good manufacturing practice (“GMP”) manufacturing. We believe that these fully integrated capabilities enable us to produce novel candidates on timelines that are shorter than the industry standard. Leveraging our science and capabilities, we have forged important partnerships to advance our innovation.
We are developing a comprehensive I-O portfolio driven by the following platforms and programs, which we intend to utilize individually and in combination:
•
our antibody discovery platforms, including our Retrocyte Display™, SECANT ® yeast display, and phage display technologies designed to drive the discovery of future CPM antibody candidates;
•
our antibody candidate programs, including our CPM programs;
•
our vaccine programs, including Prophage™, AutoSynVax™ and PhosPhoSynVax ™;
•
our saponin-based vaccine adjuvants, principally our QS-21 Stimulon ® adjuvant, or QS-21 Stimulon; and
•
our cell therapy subsidiary, AgenTus Therapeutics, Inc. (“AgenTus Therapeutics”), which is designed to drive the discovery of future adoptive cell therapy, or “living drugs” (CAR-T and TCR) programs.
We assess development, commercialization and partnering strategies for each of our product candidates periodically based on several factors, including pre-clinical and clinical trial results, competitive positioning and funding requirements and resources. As such, we have recently shifted our strategy for first approval from lung cancer to cervical cancer based on increasing competition and recent data that would have hindered our ability to pursue accelerated pathways for approval. We are currently advancing our own combination of CTLA-4 and PD-1 antibodies in second line cervical cancer.
23
We have formed collaborations with companies such as Incyte Corporation (“Incyte”), Merck Sharpe & Dohme (“Merck”) and Recepta Biopharma SA (“Recepta”). Through these alliances, as well as our own internal programs, we currently have more than a dozen anti body programs in pre-clinical or clinical development, including our anti-CTLA-4 and anti-PD-1 antibody programs (both partnered with Recepta for certain South America territories) and anti-GITR and anti-OX40 antibody programs (both partnered with Incyte). In February 2017, we amended our collaboration agreement with Incyte to, among other things, convert the GITR and OX40 programs from profit-share to royalty-bearing programs, and there are no longer any profit-share programs remaining under the collaborat ion. Pursuant to the amended agreement, we received accelerated milestone payments of $20.0 million from Incyte related to the clinical development of INCAGN1876 (anti-GITR agonist) and INCAGN1949 (anti-OX40 agonist). Concurrent with the execution of the a mendment, we and Incyte also entered into the Stock Purchase Agreement whereby Incyte purchased an additional 10 million shares of our common stock at $6.00 per share, resulting in additional proceeds of $60.0 million to us. On September 20, 2018, we, thro ugh our wholly-owned subsidiary, Agenus Royalty Fund, LLC, entered into a Royalty Purchase Agreement (the “XOMA Royalty Purchase Agreement”) with XOMA (US) LLC (“XOMA”). Pursuant to the terms of the XOMA Royalty Purchase Agreement, XOMA paid us $15.0 milli on at closing in exchange for the right to receive 33% of the future royalties and 10% of the future milestones that we are entitled to receive from Incyte and Merck, net of certain of our obligations to a third party. After taking into account our obligat ions under the XOMA Royalty Purchase Agreement, as of March 31, 2019 , we remain eligible to receive up to $450.0 million and $85.5 million in potential development, regulatory and commercial milestones from Incyte and Merck, respectively.
In December 2018, we entered into a series of agreements with Gilead Sciences, Inc. (“Gilead”) to collaborate on the development and commercialization of up to five novel I-O therapies. Pursuant to the collaboration agreements, we received an upfront cash payment from Gilead of $120.0 million following the closing in January 2019 and a milestone payment of $7.5 million in March 2019. We are eligible to receive up to an additional $1.7 billion in aggregate potential fees and milestones. At closing, Gilead received worldwide exclusive rights to our bispecific antibody, AGEN1423 (now GS-1423). Gilead also received the exclusive option to license exclusively AGEN1223, a bispecific antibody, and AGEN2373, a monospecific antibody. We filed an IND for AGEN1423 (now GS-1423) and are planning to file INDs for AGEN1223 and AGEN2373 in mid-2019. We are responsible for developing the option programs up to the option decision points, at which time Gilead may acquire exclusive rights to the programs on option exercise. For either, but not both, of the option programs, we have the right to opt-in to share Gilead’s development and commercialization costs in the United States in exchange for a profit (loss) share on a 50:50 basis and revised milestone payments. Gilead also received the right of first negotiation for two additional, undisclosed preclinical programs. At the closing, Gilead also purchased 11,111,111 shares of Agenus common stock for $30.0 million pursuant to a stock purchase agreement.
In addition to our antibody platforms and CPM programs, we are also advancing a series of vaccine programs to treat cancer. In January 2017, we announced a clinical trial collaboration with the National Cancer Institute (“NCI”), which is a double-blind, randomized controlled Phase 2 trial that is evaluating the effect of our autologous vaccine candidate, Prophage, in combination with pembrolizumab (Keytruda ® , Merck) in patients with newly diagnosed glioblastoma. Under this collaboration, we are supplying Prophage, Merck is supplying pembrolizumab and the NCI and Brain Tumor Trials Collaborative member sites are recruiting patients and conducting the trial.
Our QS-21 Stimulon adjuvant is partnered with GlaxoSmithKline (“GSK”) and is a key component in multiple GSK vaccine programs. These programs are in various stages, with the most advanced being GSK’s shingles vaccine, Shingrix. In October 2017, GSK’s shingles vaccine was approved in the United States by the FDA. In January 2018, we entered into a Royalty Purchase Agreement with Healthcare Royalty Partners III, L.P. and certain of its affiliates (together, “HCR”), pursuant to which HCR purchased 100% of our worldwide rights to receive royalties from GSK on GSK’s sales of vaccines containing our QS-21 Stimulon adjuvant. We do not incur clinical development costs for products partnered with GSK. Pursuant to our agreement with HCR, we are entitled to receive up to $40.35 million in milestone payments based on GSK’s sales of Shingrix as follows: (i) $15.1 million upon reaching $2.0 billion last-twelve-months net sales any time prior to 2024 and (ii) $25.25 million upon reaching $2.75 billion last-twelve-months net sales any time prior to 2026. We are also obligated to pay HCR approximately $25.9 million in 2021 if neither of the following Shingrix sales milestones are achieved: (i) 2019 sales exceed $1.0 billion or (ii) 2020 sales exceed $1.75 billion. GSK began selling Shingrix commercially in the fourth quarter of 2017. In February 2019, GSK reported that Shingrix sales for 2018, its first full year on the market, were over $1.0 billion.
Our business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of our collaborations. Our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of our strategy is to develop and commercialize some of our product candidates by continuing our existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations.
24
In 2017, we announced the launch of a subsidiary that is advancing our cell therapy business, AgenTus Therapeutics. The subsidiary is focused on t he discovery, development, and commercialization of breakthrough “living drugs” to advance cures for cancer patients. AgenTus Therapeutics licenses intellectual property assets from Agenus and has its own management and governance......[more]
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148717592
"AGEN/GILD:
Long shot for sure, but AGEN did fashion a deal with GILD(South San Francisco). AGEN PR today together with SEC doc confidential until May 11, 2019. AGEN is + today, has a portfolio of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies[Dr. Jedd Wolchok? MSKCC has collaborated with PPHM, its Bavituximab; CDMO spun off its mab business, developed by PPHM and UTSW to Oncologie also in Cambridge], has HQ in Mass[Oncologie?]. CDMO could be interesting to MRK and Roche[with DNA also in South San Francisco; HALO was a customer of PPHM and its wholly owned subsidiary Avid Bioservices aka CDMO; HALO is a supplier of its ENHANZE materials to Roche]
Potential merger of AGEN and CDMO, with ROCHE and/or GILD and MRK also having an interest in M/A activity.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148717592
""LEXINGTON, Mass., May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided corporate updates and reported financial results for the first quarter of 2019.
"2019 is off to a strong start. We have made significant progress towards our efforts to bring transformative treatments to cancer patients." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "In the first quarter of this year, we have strengthened our balance sheet, accelerated enrollment in our BLA path trials, and started a new clinical trial with our second generation CTLA4."
Achievements
Strengthened balance sheet
Closed on our collaboration with Gilead, which included $120M upfront, $30M equity investment and up to $1.7B in potential additional fees and milestone payments plus royalties
Received $7.5 million from Gilead as milestone payment for IND acceptance of AGEN1423 (now GS-1423), by the FDA
Enrollment in lead trials progressing; On track for BLA in 2020
Ongoing trials in cervical cancer are designed to support BLA via accelerated pathway
We plan to expand PD-1 development in additional indications through novel funding mechanisms
Enrollment proceeding in next-gen CTLA-4 trial
Started first-in-human trial with our next-gen CTLA4.
Enrollment advancing, and combinations and data expected this year
Advanced new discoveries, towards the clinic
First-in-class bispecific licensed to Gilead, GS-1423 IND accepted by the FDA
On track to file an IND for a CD137 agonist and an off-the shelf phosphorylated neoantigen vaccine
QS-21 Updates
Sales of Shingrix, containing our QS-21 Stimulon®, continue to increase; GSK projects 2019 sales will exceed $1.3Bn and pledged $100M investment to expand production of its adjuvant system
A large-scale trial with QS-21 containing Mosquirix® vaccine against malaria, began in Africa
AgenTus Cell Therapy Business:
2019 INDs are on track
Partnership and private financing discussions are underway
First Quarter 2019 Financial Results
We ended the first quarter of 2019 with a cash balance of $158 million as compared to $53 million at December 31, 2018.
For the first quarter ended March 31, 2019, we reported net income of $17 million or $0.14 per share compared to a net loss for same period in 2018 of $54 million, or $0.53 per share. In the first quarter we recognized revenue of $80 million which includes revenue from our transaction with Gilead and non-cash royalties earned.
Conference Call, Webcast and Prepared Statement Information
Date: Thursday, May 9, 2019
Time: 8:30 a.m. ET
Domestic Dial-in Number: (866) 682-6100
International Dial-in Number: (862) 298-0702
Conference ID: Agenus
Live Webcast: accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/30499
A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
About AgenTus Therapeutics, Inc.
AgenTus Therapeutics, a subsidiary of Agenus, is a preclinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough "living drugs" to advance potential cures for cancer patients. AgenTus employs naturally-derived and engineered receptors, specifically T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. AgenTus has locations in Lexington, MA and Cambridge, UK. For more information, please visit www.agentustherapeutics.com.
Forward-Looking Statements....more
Thanks. That makes sense. I really have faith in their pipeline.
Summary of a an article.
Agenus Melts Down With Blockchain
Feb. 26, 2019 11:12 AM•AGEN
Summary
Agenus stock had rallied after its deal with Gilead.
Agenus decided to raise cash with its Security Tokens for AGEN2034.
Investor reaction was negative, making the stock even more undervalued.
The Facts About PD-1 according to Feb.25 newsletter. Most of the newsletter explains the innovative BEST financing method.
• Commercial opportunity for our PD-1 in 2L cervical cancer represents up to ~$300M in estimated annual US sales for Agenus
• Commercial opportunity in expanded indications and/or combinations1 represent up to ~$1.5-2Bn in potential annual US sales
for Agenus
• Our PD-1 (AGEN2034) is on track for a BLA filing in 2020 for treatment of 2nd line cervical cancer
• Agenus’ operating plans for approval in cervical cancer are supported by our current budget; Exploiting the market beyond
cervical cancer will require additional investment
• All PD-1 antibodies that have entered late-stage clinical development have been approved; our PD-1 is in late stage development
• Combinations with PD-1 have shown improved benefit for patients - the field is moving to PD-1 combinations
• Agenus’ deep pipeline enables optimal combinations with our PD-1, including combinations with our next generation CTLA-4
• The large and growing market for approved PD-1s is estimated at ~$20B in 2019
$5 the next stop. IMO then when Agen receives it 1 billion plus pay check the sky is the limit. IMO
An Overview of AGEN finances, portfolio and platform as of early 2019
FINANCES
~ $250 million cash
~ $2.5 billion milestones
2 BLA's to be filed in 2020
PORTFOLIO (23 programs)
5 fully owned programs
7 partnered programs (average 15-20% royalties)
2 partnered option programs
3 fully owned vaccine programs
2 QS-21 adjuvant programs
2 more Agenus programs t.b.a. 2019
2 Agentus programs t.b.a. 2019
PLATFORM
recently has produced 4-6 new drugs each year.
"BEST" Crypto currency & AGEN
That's some different news alright!
http://investor.agenusbio.com/2019-01-29-Agenus-to-Launch-the-First-Asset-Backed-Digital-Security-Offering-in-Healthcare
Patients my friends, patients. We know Agens pattern is to sell on news, but with their technology, and earnings, they will stay on a bullish path and eventually take off. This is not a stock for impatient traders.
We will get there. There are alot of things happening here.
Green life I was thinking the same thing all day today. WTF is the only answer to that. We are going to $10 IMO
Only thing I can think of is the $30MM equity
WTF...great news and we crash????
It's going to be a great day !! 150 million... from Gilead... time to rock!
Thanks for info Dia76ca. What a great day today.
* * $AGEN Video Chart 01-17-2019 * *
Link to Video - click here to watch the technical chart video
I don't know when the next partnerships will be announced, however Garo speaks of "a number of partnerships in 2019". He speaks about some of these potential partnerships on the CC announcing the Gilead deal. It is all worth listening to, but the last ten minutes suggest some of these could be regional, some co-marketing, some related to particular molecules. When he uses the word "number" I think it signals more than two or three. But if you listen …. see what you think.
https://www.webcaster4.com/Player/Index?webcastId=28871&g=2bc9f07d-d029-4d2e-bf65-6b854eaf5996&uid=1455750&sid=
This presentation is very good....hope they do another soon!
http://wsw.com/webcast/jeff115/agen/
* * $AGEN Video Chart 01-07-19 * *
Link to Video - click here to watch the technical chart video
climbing the stairs.....nice and easy.....big things happening at this li`l bio! $$$$$$$$$$$ AGEN $$$$$$$$......glta
Claytrader always ignores the fundamentals! Agen is NOW well funded, with a platform that produces 4-6 new drugs a year, adding to an already large portfolio. AND there are several regional partnerships yet to be announced.
* * $AGEN Video Chart 01-03-2019 * *
Link to Video - click here to watch the technical chart video
bill and Melinda gates have just thrown some money at AGEN...
JUST KEEPS GETTING BETTER AND BETTER!!!!!
$$$$$$$$$$$$$$$$$$$$$ AGEN $$$$$$$$$$....glta
YES!!!
You're the same group of... ahem... gentlemen that used to work the PPHM board through two reverse splits and nose-diving pps.
CAVEAT EMPTOR to any innocent bystanders reading their... ahem... information for any other reason than to learn some slight of hand - or the ABC's of how to coordinate a public fleecing.
Your welcome.
(This message has been edited to take out even the most harmless of words that they could use in their efforts to hide the truth and have it once again deleted.)
Crudeoil24 may figure out who "we" are; will anybody else?
This is the Euro deal we want, but with 5x the upfront payment (at least)
some of their published results, for treating certain types of solid tumors, show great promise.....withdrawal of registration speaks volumes!!!...….great pipeline,with a new partner that can shell-out unlimited research dollars....this should see a nice jump this week......happy holidays and gltu
I am with you dirty. This will payoff IMO. By the way nice profile pic. Big buck.
shortsellers and mm`s having fun running this up and down....this is a HOLD play.......$80 billion dollar GILEAD SCIENCES....doesn't invest in trash.......AGEN has something in the pipeline that Gilead wants a piece of!!
$$$$$$$$$$$$$$$$$ AGEN $$$$$$$$$$$$$...hold your shares!
glta and HAPPY HOLIDAYS
* * $AGEN Video Chart 12-20-18 * *
Link to Video - click here to watch the technical chart video
you`d think that "cash infusion " news at 11:20 would have given it a quick jolt.......maybe news didn`t reach everyone....expect a good run back up this afternoon....glta
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1194
|
Created
|
02/12/02
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |